ForteBio's BLItz platform for cost-efficient label-free analyses of proteins using small sample volumes.
BLItz is small–taking up less surface area than a tablet personal computer–so
it can fit easily in an individual scientist's workspace and is simple to
use. It requires only four microliters of sample, which is 15 to 20 times
less volume than needed for traditional, SPR-based label-free assays or
microplate-based ELISA assays. Additionally, its Dip and Read assays utilize
disposable, ready-to-use biosensors to uniquely provide results in seconds
BLItz utilizes the same BioLayer Interferometry (BLI) technology that powers
ForteBio's flagship Octet instrumentation platform, which enables real-time
kinetics, affinity and quantitation measurements in high-throughput
applications, with unprecedented ease of use and cost-efficiency.
The new BLItz system is designed for any researcher working with proteins,
particularly those who analyze column fractions, monitor protein expression,
perform reagent QC, identify mechanism of action and signaling, and run
protein engineering studies.
ForteBio is a life science company that provides analytical systems to
accelerate biotherapeutic drug discovery and development. These systems
enable real-time, label-free analysis of biomolecular interactions,
providing information on affinity, kinetics and concentration. ForteBio’s
analytical capabilities enable significantly easier, faster and better
characterization of drug candidates, thus providing greater value in drug
development applications where existing methods have limitations in
throughput, performance and cost. The company is headquartered in Menlo
Park, California, with wholly owned subsidiaries in London and Shanghai.